Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986213 with standard-of-care regimens in recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma
2018-001070-20Phase 2
Key facts
- Status
- Terminated
- Start
- Oct 2018
- Countries
- 1
- Sponsor
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Conditions
- gastric adenocarcinomagastroesophageal junction adenocarcinoma
01
Overview
Phase 2, randomised, open-label trial of nivolumab + relatlimab, relatlimab and nivolumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 cohorts), sponsored by Bristol Myers Squibb. Primary endpoint: Objective response rate. Started Oct 2018; status: terminated.
02
Design
2 arms- Study design
- RandomizedOpen-label
Cohort A1 experimental
BMS-986213 fixed-dose combination of relatlimab and nivolumab with ramucirumab and paclitaxel.
Cohort A1 active control
Ramucirumab and paclitaxel standard-of-care active control.
03
Who it enrols
Adults with confirmed recurrent, locally advanced, or metastatic gastric or gastroesophageal junction adenocarcinoma that was not curable with local therapies; squamous cell and undifferentiated histologies were excluded.
04
Endpoints
Primary
Objective response rate
Secondary
Incidence of nonserious adverse events and serious adverse events leading to discontinuation
Beyond the preview
Go deeper on 2018-001070-20.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001070-20.